Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. Arix Bioscience plc
  6. News
  7. Summary
    ARIX   GB00BD045071

ARIX BIOSCIENCE PLC

(ARIX)
  Report
Delayed Quote. Delayed London Stock Exchange - 05/07 11:35:20 am
189.5 GBX   -0.26%
05/06Transaction in own shares
DJ
05/04Transaction in own shares
DJ
05/04Total Voting Rights
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Transaction in own shares

05/04/2021 | 12:16pm EDT
Arix Bioscience PLC (ARIX) 
Transaction in own shares 
04-May-2021 / 17:14 GMT/BST 
Dissemination of a Regulatory Announcement, transmitted by EQS Group. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Arix Bioscience plc 
 
Transaction in own shares 
 
LONDON, 04 May 2021: Arix Bioscience plc ("Arix" or "the Company") (LSE:ARIX), a global venture capital company focused 
on investing in and building breakthrough biotech companies, today announces that it purchased the following number of 
its ordinary shares of 0.001 pence each on the London Stock Exchange from Jefferies International Limited as part of a 
buyback programme announced on 22 March 2021. 
 
Date of purchase                      04 May 2021 
Aggregate number of shares purchased  97,000 
Highest price paid per share          190.00p 
Lowest price paid per share           190.00p 
Average price paid per share          190.00p 

Arix intends to retain the purchased shares in treasury.

Following settlement of the above purchase, Arix will have 133,200,800 ordinary shares of 0.001 pence each in issue (excluding 2,408,853 ordinary shares of 0.001 pence each held in treasury). This number represents the total voting rights in Arix and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), the schedule below contains detailed information of the individual trades made by Jefferies International Limited as part of the buyback programme.

[ENDS]

For more information on Arix, please contact:

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Shabnam Bashir

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

Transaction Date Transaction Time Volume Price (GBp) Platform              Transaction Reference Number 
04/05/2021       08:24:48         47,000 190.00      London Stock Exchange 00237860794TRLO0 
04/05/2021       14:32:09         50,000 190.00      London Stock Exchange 00237968141TRLO0 ----------------------------------------------------------------------------------------------------------------------- 
ISIN:           GB00BD045071 
Category Code:  POS 
TIDM:           ARIX 
LEI Code:       213800OVT3AHQCXNIX43 
OAM Categories: 2.4. Acquisition or disposal of the issuer's own shares 
Sequence No.:   102999 
EQS News ID:    1192493 
 
End of Announcement  EQS News Service 
=------------------------------------------------------------------------------------
 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1192493&application_name=news 
 

(END) Dow Jones Newswires

May 04, 2021 12:15 ET (16:15 GMT)

All news about ARIX BIOSCIENCE PLC
05/06Transaction in own shares
DJ
05/04Transaction in own shares
DJ
05/04Total Voting Rights
DJ
04/30Transaction in own shares
DJ
04/30ARIX BIOSCIENCE  : Executive Chairman Exits; COO Appointed as Interim CEO
MT
04/30Outcome of Strategic Implementation Review and Directorate Change
DJ
04/28ARIX BIOSCIENCE  : Pfizer Snaps Up Arix Bioscience Portfolio Company
MT
04/28Amplyx Pharmaceuticals acquired by Pfizer -2-
DJ
04/28Amplyx Pharmaceuticals acquired by Pfizer
DJ
04/27LogicBio announces clinical and corporate updates
DJ
More news
Financials
Sales 2021 0,50 M 0,70 M 0,70 M
Net income 2021 37,7 M 52,7 M 52,7 M
Net cash 2021 175 M 245 M 245 M
P/E ratio 2021 6,56x
Yield 2021 -
Capitalization 243 M 339 M 339 M
EV / Sales 2021 135x
EV / Sales 2022 144x
Nbr of Employees 12
Free-Float 73,3%
Chart ARIX BIOSCIENCE PLC
Duration : Period :
Arix Bioscience plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARIX BIOSCIENCE PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 221,50 GBX
Last Close Price 189,50 GBX
Spread / Highest target 35,1%
Spread / Average Target 16,9%
Spread / Lowest Target -1,32%
EPS Revisions
Managers and Directors
NameTitle
Robert Lyne CEO, COO, Secretary & General Counsel
Christian Schetter Managing Director
Marcus Karia Group Finance Director
Peregrine D. E. M. Moncreiffe Non-Executive Chairman
Graeme Smith Chief Technology Officer
Sector and Competitors
1st jan.Capitalization (M$)
ARIX BIOSCIENCE PLC-13.47%339
INVESTOR AB (PUBL)21.67%66 862
CK HUTCHISON HOLDINGS LIMITED18.95%31 949
AB INDUSTRIVÄRDEN (PUBL)19.91%16 788
HAL TRUST28.89%15 636
KINNEVIK AB1.34%14 458